ImageneBio (NASDAQ:IMA) Trading Up 0.5% – Here’s Why

ImageneBio, Inc. (NASDAQ:IMA)’s share price shot up 0.5% during mid-day trading on Wednesday . The company traded as high as $7.40 and last traded at $7.39. 30,752 shares changed hands during mid-day trading, an increase of 30% from the average session volume of 23,604 shares. The stock had previously closed at $7.35.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on IMA shares. Wedbush cut shares of ImageneBio from a “neutral” rating to an “underperform” rating in a research report on Tuesday, November 25th. Weiss Ratings began coverage on shares of ImageneBio in a report on Wednesday, October 22nd. They issued a “sell (e-)” rating for the company. Leerink Partners began coverage on shares of ImageneBio in a research report on Friday, October 24th. They issued an “outperform” rating and a $30.00 price objective for the company. Finally, Wall Street Zen lowered ImageneBio from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, ImageneBio presently has an average rating of “Hold” and an average price target of $26.50.

ImageneBio Price Performance

The stock’s 50 day moving average is $6.64 and its two-hundred day moving average is $9.54. The firm has a market capitalization of $82.62 million, a P/E ratio of -0.92 and a beta of 0.43.

ImageneBio (NASDAQ:IMA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($2.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.47) by ($1.44). As a group, equities research analysts expect that ImageneBio, Inc. will post -0.91 EPS for the current year.

Insider Transactions at ImageneBio

In other news, Director Joseph P. Slattery acquired 16,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 24th. The stock was purchased at an average price of $5.99 per share, for a total transaction of $95,840.00. Following the completion of the acquisition, the director owned 16,000 shares in the company, valued at $95,840. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 5.94% of the company’s stock.

Hedge Funds Weigh In On ImageneBio

Several institutional investors and hedge funds have recently made changes to their positions in IMA. Bridgeway Capital Management LLC acquired a new position in shares of ImageneBio in the 3rd quarter valued at approximately $104,000. NewEdge Advisors LLC bought a new position in ImageneBio in the third quarter valued at approximately $106,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of ImageneBio in the third quarter valued at approximately $144,000. Aldebaran Capital LLC bought a new stake in shares of ImageneBio during the third quarter worth $159,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of ImageneBio during the third quarter worth $197,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.